SUBSCRIBE
SUBSCRIBE
News   Policy

MannKind Corporation Faces Crucial Test on Insulin Device; Many Bet it Will Fail

January 6, 2010 | 
1 min read
Bookmark and Share

Reuters -- MannKind Corp (MNKD.O) faces a crucial test next week as U.S. regulators prepare to rule on the company's inhaled insulin device, and many investors are betting it will not be approved.
Regulatory
MORE ON THIS TOPIC
Minimal Clip Art Collage. Pop Vector Design Composition with bright bold geometric shapes, halftone objects for ad, animation etc
Approvals
First Commissioner’s Priority Review Approval Goes to Decades-Old Antibiotic
December 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs
December 10, 2025
 · 
1 min read
 · 
Heather McKenzie
Two businessmen negotiating with big speech bubbles
Rare diseases
Saol To Pitch Ultrarare Disease Drug as “Poster Child” for RDEP Program
December 9, 2025
 · 
2 min read
 · 
Heather McKenzie
FDA signage at its headquarters in Maryland
FDA
CAR-T Developers Will Need Randomized Trials as FDA Eyes Tighter Approval Requirements
December 9, 2025
 · 
2 min read
 · 
Tristan Manalac